HDST-M Stock Overview
Operates in the biotechnology industry in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
HBL - Hadasit Bio-Holdings Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.47 |
| 52 Week High | ₪0.88 |
| 52 Week Low | ₪0.19 |
| Beta | 0.82 |
| 11 Month Change | 82.75% |
| 3 Month Change | 33.14% |
| 1 Year Change | -23.23% |
| 33 Year Change | -91.17% |
| 5 Year Change | -89.20% |
| Change since IPO | -99.84% |
Recent News & Updates
Shareholder Returns
| HDST-M | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | -4.9% | -2.8% | 0.8% |
| 1Y | -23.2% | -8.2% | 22.8% |
Return vs Industry: HDST-M underperformed the IL Biotechs industry which returned -8.2% over the past year.
Return vs Market: HDST-M underperformed the IL Market which returned 22.8% over the past year.
Price Volatility
| HDST-M volatility | |
|---|---|
| HDST-M Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in IL Market | 7.3% |
| 10% least volatile stocks in IL Market | 2.9% |
Stable Share Price: HDST-M's share price has been volatile over the past 3 months compared to the IL market.
Volatility Over Time: Insufficient data to determine HDST-M's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 2 | Yoram Azulai | www.hbl.co.il |
HBL - Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It operates in the fields of oncology, regenerative medicine, and inflammatory disease. The company develops biological drugs; and plasma RNA biomarkers for colorectal cancer.
HBL - Hadasit Bio-Holdings Ltd Fundamentals Summary
| HDST-M fundamental statistics | |
|---|---|
| Market cap | ₪5.17m |
| Earnings (TTM) | -₪7.66m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs HDST-M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HDST-M income statement (TTM) | |
|---|---|
| Revenue | ₪0 |
| Cost of Revenue | ₪0 |
| Gross Profit | ₪0 |
| Other Expenses | ₪7.66m |
| Earnings | -₪7.66m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 59.0% |
How did HDST-M perform over the long term?
See historical performance and comparison